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ABSTRACT

THE ROLE OF INSULIN, INSULIN-LIKE GROWTH FACTORS I AND II, INSULIN¬
LIKE GROWTH FACTOR BINDING PROTEIN 3, AND THEIR RECEPTORS IN
THE REGULATION OF HUMAN FETAL GROWTH. D. Elizabeth Le (Sponsored by
Harold R. Behrman). Department of Obstetrics and Gynecology, Yale University, School
of Medicine, New Haven, CT.

This investigation was undertaken to determine the relationship between normal
human fetal growth and the levels of insulin, insulin-like growth factors I and II (IGF-I
and IGF-II), insulin-like growth factor binding protein 3 (IGFBP-3), and their receptors
in both the maternal and fetal compartments.
Serum (n = 20) and amniotic fluid (AF) (n=7) samples were obtained from normal
pregnant women, their term neonates (n=20) between 38-41 weeks gestation, and fetuses
(n = 32) via cordocentesis between 21-36 weeks gestation. Neonates were designated as
appropriate for gestational age (AGA) if their weights were between the 10th and 90th
percentiles and large for gestational age (LGA) if they were greater than the 90th
percentile. Newborns were also classified as small or large if their weights were below
or above the 50th percentile for newborns of the same age. Serum and AF samples were
analyzed for levels of insulin, IGF-I, IGF-II, and IGFBP-3 by radioimmunoassay.
Insulin and type 1 IGF receptors were assessed by immunohistochemistry from placental
tissues.
Fetal serum IGF-I, IGF-II, and IGFBP-3 remained stable between 21-36 weeks.
At term, large neonates had increased IGF-I and IGFBP-3 levels compared to levels
measured during 21-27 weeks and 28-36 weeks gestation (x + SEM; [IGF-I] 53 ± 8

IV

ng/ml and 58 + 7 ng/ml vs. 86 + 6 ng/ml, p<0.05; [IGFBP-3] 0.08 ± 0.08 /u,g/ml and
0.08 ± 0.05 /xg/ml vs. 1.10 ± 0.04 /xg/ml).

There was a direct correlation between

gestational age and birth weight and the levels of IGF-I (r= +0.297, p<0.05;
r= +0.564, p<0.02, respectively) and IGFBP-3 (r= +0.386, p<0.01; r=+0.503,
p<0.002, respectively).

IGF-I, IGF-II, and IGFBP-3 levels, but not insulin, were

significantly higher in large neonates compared to small neonates.

Insulin and type 1

IGF receptors were detectable in placental membranes as early as 7 weeks gestation.
These data demonstrate the bioavailability of fetal IGF-I, IGF-II, IGFBP-3, and
type 1 IGF receptors throughout pregnancy.

Fetal serum IGF-I and IGFBP-3 were

shown to be associated with fetal age and birth weight in normal pregnancies.
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INTRODUCTION

Normal Fetal Growth
Human fetal growth consists of forty-four cell divisions from the time the ovum
is fertilized to delivery at term and is characterized by three phases:

hyperplasia,

hyperplasia with concomitant hypertrophy, and hypertrophy. 9,64 By the third week, the
embryo is composed of three germ cell layers and from the fourth to the eighth week,
organogenesis takes place. By the end of the 16th week, the intestines have returned to
the abdominal cavity and the genitalia are well-defined.

During this period, all of the

limbs have developed with ossification also in progress.
During the preconceptional period, genetics, maternal nutritional state, and
biological and environmental factors may affect subsequent development of the
conceptus.

The mechanism of genetic control of cell growth and differentiation that is

the determinant of species size at birth is poorly defined. Approximately 20% of birth
weight is attributable to fetal genotype. The male sex is associated with increased birth
weight of 150-200 gm when compared to the female sex. Another 20% of the variation
is due to maternal influence including race, age, height, weight, and parity. 64 During
the embryonic period (conception through the first 8 weeks) teratogens and uncontrolled
maternal diabetes can change normal growth patterns as this

is the period of

organogenesis. From the end of the embryonic period through delivery, nutrition, 95
hypoxia, 51 and placental, hormonal, environmental, 109 and genetic factors can alter
growth.
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The birth weights of infants delivered at various gestational age follow a growth
curve in which fetal weight increases exponentially until the latter part of gestation, when
fetal growth rate slows leading to a sigmoidal-shaped curve. The curve shows a steady
rate of increase from approximately 24 weeks to 37-39 weeks, and in most series, there
is flattening of the curve at 37-39 weeks. 60,103 In general, the rate of growth is slower
after 30 weeks of gestation in twins and after 36 weeks in singletons. After 44 weeks,
there is a decrease of average birth weight. 91
Acceleration of fetal weight during the last trimester is manifested by an 11-fold
increase in fat, 3-fold increase in protein, and an overall 2.5-fold in weight. 91 The fetus
grows at approximately 1.5% per day or 15 gm/kg/day during this period. Nonfat dry
weight increases at approximately 2.25 gm/kg/day and fat accretion increases at
approximately 3.5 gm/kg/day, although the latter is more variable. The remainder of the
15 gm represents water accretion. 64
The fetal liver is the major site for protein synthesis in the latter part of gestation
and is regulated by substrate availability and modulation of synthetic apparatus by
endocrine and other factors. Glucose is the major substrate utilized by the growing fetus
and is stored in the fetal liver as glycogen; it is transplacentally distributed in the fetal
circulation via facilitated transport.

Glucose storage dramatically increases after 36

weeks for enhanced glycolysis capacity for the fetus during periods of stress in the
intrapartum and early newborn periods. 64
Placental growth, which follows the same three phases of development as the
fetus, is also critical for fetal growth. Normal placentas increase in size almost linearly
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up to 36 weeks and are influenced by human placental lactogen (hPL) and human
chorionic gonadotropin.

Maternal serum hPL increases with gestational age until it

plateaus at 37 weeks with a slight decline between 37-40 weeks. One of its action is to
block maternal utilization of glucose and to promote mobilization and utilization of free
fatty acids thereby increasing the amount of glucose available to the placenta for transfer
to the fetus. 22 Uteroplacental constraints appear to become the major factor for growth
at 3000-3200 gm in normal pregnancy. 74

Deviant Growth
Neonates are designated as small for gestational age (SGA) when they are less
than the 10th percentile for birth weight, appropriate for gestational age (AGA) when
they are between the 10th and 90th percentiles, and large for gestational age (LGA) when
they are greater than the 90th percentile. However, statistically, 10% of infants should
be below the 10th percentile and 10% should be above the 90th percentile regardless of
medical interventions. This group, therefore, may reflect biological diversity as well as
deviant growth.
Intrauterine growth retardation (IUGR) is defined as transient or persistent
decrease in the rate of fetal growth that exceeds a given percentage of either the earlier
individual growth rate or the normal expected growth rate.

Type I growth restriction

results in symmetric reduction in growth of all tissues because malnutrition occurs during
hyperplasia leading to organs that are permanently reduced in cell number.
therefore is not necessarily underweight for height.

The fetus

In Type II growth restriction.
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undernutrition occurs during the hypertrophic phase leading to reduction in cell size. It
does not become significant until the third trimester.

Normal fetal length is usually

preserved with head sparing growth and soft tissue wasting. This process is reversible
with improved nutrition. 15
Early menarche, low prepregnancy weight and height, and short interpregnancy
intervals have been associated with increased risk of delivering small babies. Delivery
of growth

retarded infants

predisposes to

growth retardation

in subsequent

pregnancies. 31
From 36 weeks gestation, those with a birth weight of less 10% carry a 10% risk
of poor perinatal outcome. 75 Interestingly, almost 50% of perinatal morbidity occurs
in neonates with normal birth weights. Scott and Usher 88 found that perinatal asphyxia
was more common in type II IUGR infants than type I, and Hill et al. 45 demonstrated
that regardless of birth weight, long-term neurological morbidity was more frequent
among neonates born with soft tissue wasting seen in type II growth restriction. Low et

al. 59 have found that type II IUGR babies have an accelerated growth phase during the
first 3 months post delivery, although at 12 months of age, they remain smaller than
AGA babies.

All IUGR infants are also prone to meconium aspiration, polycythemia,

and hypoglycemia. 31

Since IUGR often occurs in mothers who are not grossly

malnourished, it is likely that a subtle interplay exists between nutrients levels and
inadequate placental perfusion and transfer of nutrients. 30
The severity of growth restriction is not only related to the availability of
substrate levels but is also dependent upon the maternal underlying nutritional state, the
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timing, and the severity and duration of deprivation.

Chronic reduction in placental

perfusion and other placental diseases have been uniformally associated with smaller
placental size and asymmetric fetal growth in a linear and inverse relationship. 88,111 In
longitudinal studies, changes in uterine blood flow correlate directly with changes in the
growth rate of tissue, and levels of oxygen, glucose, and lactate in fetal circulation are
unchanged until long after morphometric evidence of growth restriction is well
established. 16'19,100 Early adaptive measures in response to growth retardation probably
include normal physiologic responses to down regulate the demand for the substrate. If
the stressor continues, regional distribution of placental blood flow shunts toward the
organs most essential for survival. 15 It is also thought that the placenta could respond
to decreased delivery of substrates by releasing one or more growth inhibiting substances.
Vascular ligation in the guinea pig resulted in identification of a protein moiety in the
umbilical venous plasma of a growth retarded fetus which clearly suppresses protein
synthesis in cultured hepatocytes. 49 Charlton and Johengen 14 showed that decreased
fetal/placental weight induced by progressive placental emboli damage can be prevented
by hyperalimentation via intravenous but not via intragastric route.

Thus limited

substrate availability rather than placental damage and a reduction in flow is probably the
event leading to restricted growth.

This study also confirms the interdependence of

substrate cycling of the placenta and liver. Therefore, the data suggest that adequacy of
the normal placentation process itself coupled with an autoregulated, substrate-dependent
growth inhibitory response to a variety of restrictive stimuli is necessary.
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In the majority of asymmetric IUGR, there is reduced maternal levels of hPL. 64
Since it reflects placental mass and not low fetal weight, low levels of this hormone can
be used to identify IUGR caused by small placentas.

Conversely, in multiple and

diabetic pregnancies, high levels of hPL have been associated with above normal
placental weight. 92 Other hormonal and metabolic changes of a growth-suppressed fetus
at term include elevated catecholamine, cortisol, glucagon, beta-endorphin, essential and
branched chain amino acids, and reduced prolactin, thyroxin, insulin, insulin-like growth
factor I

(IGF-I),

insulin-like growth factor II (IGF-II), glucose, lactate, and

triglycerides. l’13,29 ’90,107
In the U.S. more than 100,000 LG A babies are born each year with the overall
incidence at 3.1-5.3%. 47 Macrosomia is associated with high maternal and perinatal
morbidity and mortality.

Nelson et al. 71 estimated that there are 164 perinatal deaths

per 1000 births. The perinatal morbidity rate is at least twice that of normal sized infants
and the mortality rate is at least 5 times higher. 83 This risk is even greater for those
with birth weights above 4500 gm.

There

is also increased association with

hyperglycemia, hypocalcemia, hyperbilirubinemia, polycythemia, cardiac failure, and
cerebral edema from trauma or asphyxia. In addition, the condition poses increased risks
of vagina! laceration, pelvic hematomas from forceps use, and uterine atony and
hemorrhage to the mother. 67 Certain factors have been empirically associated with fetal
macrosomia such as history of large babies, 94 multiparity, maternal obesity (greater than
15% overweight), excessive weight gain (greater than 35 pounds) during pregnancy,
Class A diabetes, and post-dates delivery. 54

7
There are two types of macrosomia—mechanical and metabolic.

In the former,

fetuses are proportional, and difficult deliveries are secondary to shoulder dystocia,
which is

related to increased shoulder circumference and not simply to high birth

weight. 2 53 69 Shoulder dystocia is associated with a morbidity rate of 3.3% for babies
who weigh 4100-4325 gm and 8.2% for those greater than 4500 gm. Some fetuses grow
as expected during the third trimester and become macrosomic only because they do not
deliver at 38 weeks and appear to continue growing.

Other fetuses show growth

acceleration in the third trimester and thus are macrosomic regardless of when they are
delivered. 1
Metabolic or asymmetric macrosomia is often associated with diabetes mellitus
where hypertrophy and hyperplasia account for organ enlargement, which subsequently
results in mechanical macrosomia and possibly death in utero. 7U

Susa et al. 97

demonstrated hepatomegaly, cardiomegaly, and a large increase in adipose tissue
deposition in the rhesus monkey associated with fetal hyperinsulinemia.

The Role of Insulin in Fetal Growth
Insulin is present in the fetus as early as nine weeks gestation 93 and increases
with gestational age.

The hormone is entirely of fetal origin as it does not cross the

placental barrier. Only after 20 weeks gestation is the insulin response to glucose clearly
manifested. 6 In addition to the placenta 77, insulin receptors have also been identified
in other fetal tissue and are characterized by increased binding capacity for insulin and
failure to down regulate receptor number in presence of hyperinsulinemia. 72

8
Overall, diabetic patients have 15-45% incidence of producing macrosomic
infants. 56

In uncontrolled diabetic mothers, fatty acid transport is increased which

contributes significantly to the growth of the fetus in the third trimester resulting in a
macrosomic baby.
tissues

such as

tissue. 51,70

Fetal hyperinsulinemia increases the activity of insulin-sensitive

fat,

These

muscle, and
metabolic

abdominal 73,98 circumferences.

liver,

resulting in

effects often

increased formation

result in

greater

of soft

shoulder 68 and

Overgrowth of infants is manifested by either normal

fetal length but obese or one with large body dimensions for gestational

age but not

obese. Fetal hyperinsulinemia is associated with increased serum IGF-I 44 whereas fetal
pancreatectomy is associated with decreased levels 40.
also promotes placental storage of triacylglycerol.

The high insulin/glucagon ratio

During the neonatal period, 75% of

infants of pregestational diabetic and 25% of infants of gestational diabetic mothers
develop hypoglycemia. The infants whose metabolic state has been altered have impaired
ability

to

react

to

temporary

hypocaloric

stress

since

often

they

are

also

hypoglucagonemic and have impaired glycogenolysis. Other complications include birth
asphyxia,

respiratory

distress

syndrome,

cardiac

dysfunction,

hypocalcemia,

polycythemia, jaundice, small left colon syndrome, and various congenital anomalies. 96
There are cases however such as well controlled diabetes, where fetal insulin
levels are presumably normal but fetal size is nevertheless excessive.

This has lead to

the speculation that other factors or peptides may also have a significant growth
promoting influence. Insulin, IGF-I, and IGF-II are closely related molecules; therefore
it is conceivable that IGFs may also have a significant role in fetal growth.
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Insulin-like Growth Factor I (IGF-I) and Insulin-like Growth Factor II (IGF-II)
Mechanisms of control of placental and fetal growth are likely to be related and
are also likely to involve the same peptides that regulate extrauterine growth, namely
insulin, IGF-I, IGF-II and growth hormone (GH).
IGF-I is a basic, single chain polypeptide containing 70 amino acids with a
molecular mass of 7.6 kD.

IGF-II is slightly acidic consisting of 67 amino acids and

weighing 7.4 kD; it has 68% homology with IGF-I, and both share with insulin structural
homology, three-dimensional configuration, and the property of causing effects associated
with growth hormone-dependent growth of humans. These effects include the stimulation
of glucose and amino acid transport, lipid synthesis from glucose, glycogen and protein
synthesis, and inhibition

of lipolysis. 96' 112

Insulin, however, differs from the IGF

peptides in the mechanism of transport in plasma; insulin is carried unbound while both
IGF-I and IGF-II are associated with specific carrier proteins via non-covalent bonds.
Several studies have shown the presence of IGF-I and expression of its gene from
rat kidney, lung, liver, and heart 26 and human fibroblasts, 20 hepatocytes, hepatic
hemopoietic cells, intestine and kidney tubules, adrenal cortical cells, and skeletal and
heart muscle fibers. 43

Additionally, there appear to be developmental changes in the

expression of IGF-II, with increased levels of the mRNA that encodes this peptide in
second trimester placentas, as compared to first trimester and term placentas. 89 In term
diabetic gestations, increased placental expression of the IGF-II-specific mRNA is
observed, with overlap of its levels of expression of the mRNA in diabetics and normal
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controls. 89 However, relevant data are not available as to the clinical severity of the
diabetes in this study, or the adequacy of glycemic control during pregnancy.
Although two somatomedins (IGF-I and IGF-II) play a role in the GH-dependent
growth of humans after birth, their production during fetal life appears to be independent
of GH.

The fetal pituitary does not seem to be necessary for maintenance of serum

IGF-I as anencephalic newborns have normal levels in cord serum. 24

It has been

reported that a single ovine placental lactogen injection in the hypophysectomized rat
could normalize serum IGF-I and pregnant GH-deficient women have normal IGF-I
levels. 24
Although it has not yet been proven that IGF-I stimulates fetal growth, three lines
of evidence suggest that they influence fetal growth. First, IGF-I and IGF-II are capable
of stimulating the proliferation of fetal cells from various species, including human.
Studies have reported that IGF-I could promote proliferation of rat fibroblasts, 3
calvaria, 11 and osteoblasts, 85 chick fibroblasts, 80 and human fibroblasts 21 ■ 106 and
cartilage; 4 protein synthesis in the rat 11 and chick cartilage; 36,42 glycogen synthesis in
rat

osteoblasts, 85 myoblasts, 32

and hepatocytes; 34

osteoblasts 86 and chick myoblasts. 87
trophoblast. 104

and

differentiation of rat

IGF-II can activate proliferation of placental

Phillips et al. 76 have also shown that the administration of IGF-I to

neonatal rats, but not GH, stimulated growth.

Second, studies have demonstrated that

IGFs in fetal plasma are of fetal origin since they are not transported from mother to
fetus by the placenta. The liver appears to be the major source of serum IGFs in human
and the peptides have been measured in extracts of many tissues. 25 In addition, IGF-I

11
and IGF-II have been detected in term and preterm placenta suggesting that they are
involved in placental growth. 33,65 Third, several studies have demonstrated the direct
synthesis of IGFs by fetal tissues. 20,43,101
The involvement of IGF-I and IGF-II in fetal growth has long been suspected,
since deviant fetal growth, for example in diabetes, could not be explained by insulin
levels only. Although studies have suggested that maternal serum concentrations of IGF
increase during normal pregnancy, investigations of its relationship to infant size in
normal pregnancy have yielded conflicting results. Multiple investigators, using a variety
of assay techniques

non-longitudinal studies have reported conflicting data regarding

IGF-I and IGF-II levels in cord blood samples both during fetal life and at birth. 10,35,39,
40, 55. 82, 102, 105

IGF Binding Proteins (IGFBP)
Binding proteins for IGF peptides have previously been purified by affinity
chromatography
hepatoma cells 78

from culture

media

conditioned by

rat BRL cells 61 and

human

and by conventional biochemical techniques from human amniotic

fluid. 28 Five classes of IGFBP have been identified in human serum; the 3 most wellcharacterized have been designated as IGFBP-1, IGFBP-2, and IGFBP-3.

More than

98% of IGFs in normal post-natal serum is bound to IGFBP-3, a large molecular mass
(150 kD) complex which is GH-dependent, thus causing circulating IGFs levels to be
higher than the concentration in the tissue. This binding protein does not seem to appear
until the second half of human gestation. 27

IGFBP-1 (also known as binding protein-

28, placental protein 12, and pregnancy-associated endometrial a,-globulin) is 28 kD in

12
size and GH-independent. It has been shown to be influenced by insulin in both normal
and diabetic patients. 108 Additionally, IGFBP-1 derived from amniotic fluid has also
been shown to be a cell growth inhibitor. 58 IGFBP-2, 40 kD binding protein isolated
from the rat liver cell line BRL-3A, 61 has a molecular equivalent in human cerebral
spinal fluid, which has a selective affinity for IGF-II. 48
The binding of IGF-I and IGF-II to carrier proteins abolishes the insulin like
properties of the free polypeptides. 52 Thus carrier proteins may also play an important
role in the action of plasma IGFs and consequently may influence the regulation of fetal
growth. 46’112

IGF Receptors
Both type 1 and type 2 receptors for IGF have been identified and partially
purified from fetal tissues 81 and the placenta 89 supporting the role of IGFs in stimulating
fetal growth. Type 1 is a 350 kD glycoprotein consisting of 2 extracellular cn-subunits,
weighing approximately 130 kD, which contain the hormone binding site and 2
transmembrane
activity. 62

6-subunits

approximately

95 kD

with

intrinsic tyrosine kinase

The type 1 receptor has high affinity for IGF-I, somewhat lower and

sometimes equal affinity for IGF-II, and low affinity for insulin (0.1-1.0%). Casella et
al. 12 demonstrated that the type 1 receptor in the human placenta possess a distinct high
affinity binding site for IGF-II. In fetal rat hepatocytes, Freemark et al. 34 showed that
IGF-I was more potent than either IGF-II or insulin in stimulating glycogen synthesis,
suggesting that the type 1 receptor can mediate insulin-like effects. The Type 2 receptor
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is 250 kD and a monomeric transmembrane protein whose mechanism of intracellular
signal transduction is unclear. It has high affinity for IGF-II, low to moderate affinity
for IGF-I, and no interaction with insulin. IGF-I, like insulin, can down regulate type
1 and 2 receptors.

IGF-II has not been demonstrated to have such influence.

Since IGF-I and IGF-II are thought to initiate biologic actions, which include
inducing mitosis, glucose oxidation, and amino acid uptake and by binding to cell surface
receptors 24,104 and the expression of type 1 and type 2 IGF receptors also appears to be
maximal during the second trimester, 84 the suggestion has been made that IGFs regulate
the hyperplastic stage of fetoplacental growth, with insulin assuming a major role during
the third trimester.

Purpose and Hypothesis
The objective of this investigation was to study longitudinally the relationship
between

normal human fetal growth and the levels of insulin, IGF-I, IGF-II, and

IGFBP-3 in both the maternal and fetal compartments and to determine the presence of
their receptors in placental membranes during development of the human fetus. We have
hypothesized that in addition to insulin, IGF-I, IGF-II, and IGFBP-3 are involved in the
regulation of fetal growth and thus their levels will vary among neonates of different
birth weights in normal pregnancies.
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METHODOLOGY

Subject Population. Seven patients who underwent voluntary termination of pregnancy
(VTOP) by dilatation and evacuation (7-11 weeks gestation), 27 who delivered vaginally
or by cesarean section (C-section) (38-41 weeks gestation), and 32 who underwent
percutaneous umbilical blood sampling (PUBS) for various diagnostic purposes (21-36
weeks gestation) participated in this investigation.

Patients were excluded if they did

not meet the criteria for normal: absence of diabetes, elevated 1 hour glucose tolerance
test, hypertension, or other complications during pregnancy.

All fetal blood samples

from PUBS used in this study were from fetuses who had Rh disease.

However,

ultrasound measurements indicated that each fetus’s estimated weight and size were
appropriate for gestational age.

All subjects were Caucasians and ranged from 20-38

years old except for the VTOP group in which there were some were African American
patients and some who were less than 18 years old. Oral consent was sought from each
patient regarding collection of blood and membrane samples and of pertinent data from
the medical records.

This research project was approved by the Human Investigation

Committee of the Yale University School of Medicine.

Index of Growth.

Delivery weight was chosen as the index of fetal size.

Using the

gestational-weight curves established by Lubchenco et al., 60 neonates were designated
as AGA (between the 10th and 90th percentiles for birth weight) or LGA (> the 90th
percentile for birth weight) and small or large if their weights were below or above the
50th percentile for newborns of the same age.
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Medical History Collection. (Performed by author). For each fetus/neonate entered in
the study, the following information was recorded from the chart: mother’s age, weight
and previous pregnancy history; medical history including presence of diseases which can
affect fetal growth and pregnancy outcome, medications, and pregnancy complications;
and fetal delivery information including gestational age, mode of delivery, sex, and birth
weight and length. Gestational age was calculated in completed weeks from the first day
of the mother’s last menstrual period.

Serum and Amniotic Fluid Collection. (Performed by author). At the time of vaginal
deliveries and C-sections, at least 2 ml of blood each was collected in a vacutainer tube
containing ethylene dinitrilo tetraacetic acid (EDTA) from the mother via venipuncture
and from the neonate via puncture or drainage from the umbilical cord which contained
both arterial and venous blood.

Fetal blood samples were obtained by direct puncture

of the umbilical vessel under ultrasound guidance. At C-section deliveries, at least 2 ml
of amniotic fluid was also collected. All samples were either immediately spun down at
4,000 x g for 10 minutes or placed on ice and spun within 2 hours. They were stored in
aliquots of 0.5 ml at -20° C until the time of assay.

Tissue Procurement.

(Performed by author).

Upon delivery of the placentas from

C-sections, neonatal blood was collected and the placentas placed on ice. The amnion,
chorion/decidua, and placenta were isolated by visual inspection and washed with cold
saline to remove adherent blood. Placentas from VTOP were immediately placed in cold

16
saline on ice and rinsed to remove as much blood as possible.

A 2 cm x 2 cm sample

of each tissue was placed in 1.5% glutaraldehyde fixative (25% glutaraldehyde [Sigma
G5882], 0.04 g/ml paraformaldehyde, 0.36% sodium hydroxide, and 10% autoclaved
phosphate buffered saline (PBS), which contained 8.1 mM sodium phosphate dibasic
anhydrous, 1.9 mM sodium phosphate monobasic, 145 mM sodium chloride, and 1 ml
0.5 mM EDTA at pH 7.4) and stored for at least 6 hours or overnight in the dark at
room temperature.

This phase of tissue collection did not exceed 30 minutes.

The

samples were then washed twice with PBS at room temperature and put in cassettes,
which were placed in 60% ethanol (ETOH) for at least 6 hours or overnight at 4°C.
Tissue samples were embedded in paraffin blocks within 24 hours, sectioned (5 /xm), and
placed on glass microslides for immunohistochemical staining (performed by Adel
Kusnitz at Yale University School of Medicine).

Immunohisto chemistry
Reagents.

PBS was sterilized using a millipore (0.22 /xm) syringe filter and

mixed with 1% bovine serum albumin (BSA).

Blocking protein (human serum from

normal adult volunteer) was mixed with PBS in a ratio of 1:67. The serum was collected
immediately after venipuncture, stored at -20° C in aliquots, and used without refreezing.
The primary antibodies (monoclonal antibody against insulin receptor, extracellular
domaine, [ChemiconInternational, Inc., Temecula, CA] and monoclonal antibody against
Type 1 IGF receptor, [Oncogene Science, Manhasset, NY]) and secondary antibody
(biotinylated anti-mouse IgG (Vector, Burlingame, CA) were mixed with PBS/1 % BSA
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in a 1:10 ratio.
intensity.

These dilutions were previously titered to give an appropriate staining

Streptavidin-horseradish peroxidase (Zymed Labs, Inc., So. San Francisco,

CA) was prepared with PBS/1 % BSA in a ratio of 1:100.

The chromogen solution,

diaminobenzine tetrahydrochloride - A (DABA), contained 0.045% hydrogen peroxide
and 6.7%

3,3’-diaminobenzidine isopac of tetrahydrochloride

[Sigma D9015]

in

phosphate buffer (PB), which consisted of 8.1 mM sodium phosphate dibasic anhydrous
and 1.9 mM sodium phosphate monobasic at pH 7.4.

Procedure. (Performed by author). The tissue sections on the microslides were
deparafinized by immersing in xylene for 7 minutes 3 times and rehydrated by
sequentially dipping in 100% ETOH for 2 minutes; 75% ETOH for 2 minutes; 50%
ETOH for 2 minutes; 25% ETOH for 2 minutes; double distilled water for 2 minutes;
1% hydrogen peroxide for 15 minutes; and PBS 5-6 times. The blocking solution was
applied to each section and incubated in a humidified tray for 10 minutes at room
temperature.

The excess blocking solution was then tapped off.

Next, the primary

antibody solution was applied to each tissue section. The tissue was then incubated in
a humidified chamber at 4° C for 20 hours. The slides were allowed to return to room
temperature, and each was gently rinsed with PBS 2 to 3 times. After the secondary
antibody was placed on each tissue section, all samples were incubated for 60 minutes
at room temperature.

The slides were then rinsed with PBS 2-3 times. The next stage

consisted of applying streptavidin-horseradish peroxidase on the tissue and incubating for
30 minutes at room temperature. The slides were then rinsed with PBS and kept covered
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with the buffer to keep from drying until the entire batch was completed.

DABA was

used to develop the tissues (approximately 5 minutes). Slides were monitored under the
microscope to prevent excessive background.

The peroxidase-antiperoxidase reactions

were terminated by washing sections in distilled water.

The tissue sections were then

dehydrated by sequentially dipping in gradually increasing concentration of ETOH: 25%
ETOH for 2 minutes; 50% ETOH for 2 minutes; 75% ETOH for 2 minutes; 100%
ETOH for 10 minutes 2 times; and xylene for 10 minutes 2 times. Coverslips were then
placed on the tissue sections using Cytoseal.

Positive control consisted of identifying

insulin and type 1 IGF receptors in 2 fetal liver samples (19 and 21 weeks gestation).
Negative controls were done by omitting the primary antibody, the secondary antibody,
streptavidin-horseradish peroxidase, or DABA and were included with each batch of
slides that was stained.

Biochemical Assays
Radioimmunoassay (RIA) for insulin.

Insulin concentrations were measured in

maternal and neonatal sera and amniotic fluid by Aida Groszmann at Yale University
School of Medicine.

Reagents.

The reagents used were supplied in a commercial double

antibody RIA kit (Ventrex Laboratories, Portland, ME). They included (1) assay buffer
(protein stabilizer and a preservative); (2) insulin antiserum (guinea pig anti-insulin in
buffer with a protein stabilizer and a preservative); (3) insulin tracer (I25I-insulin in
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buffer with a protein stabilizer, normal guinea pig serum, and 0.1% sodium azide as a
preservative);

(4) precipitating

agent (goat anti-guinea pig gamma-globulin and

polyethylene glycol (PEG) in buffer with 0.1% sodium azide as preservative; (5) insulin
standards (7 concentrations [2.5-300 /xU/ml] of porcine insulin in buffer); and (6) insulin
controls (lyophilized porcine insulin in human serum with 0.1% sodium azide as a
preservative, which was reconstituted with distilled water).

Procedure.

All standards, controls, and samples were assayed in

duplicate. Three hundred n 1 of assay buffer were placed in 2 non-specific binding tubes,
and 200

/jl\

into 2 maximum binding tubes.

Two hundred /xl of each standard, control

and sample were placed in the remaining tubes. Next, 100 /xl of insulin tracer was added
to each tube including 2 for total counts followed by 100 /zl of insulin antiserum into all
tubes except the total count and non-specific binding tubes. All tubes were then vortexed
and incubated for 90 minutes at room temperature.

One ml of precipitating agent was

then added to all tubes, which were vortexed and incubated for 10 minutes at room
temperature. The tubes were then centrifuged at 1,500 x g for 10 minutes at 4°C. The
supernatant of each tube except the total count tubes was decanted and the rim was
blotted dry.
counter.
the

The radioactivity in all tubes was counted for 1 minute in the gamma

For each standard concentration, the percentage binding was calculated using

formula

(counts/minutes

of

standard

-

counts/minutes

of

non-specific

binding)/(counts/minutes of maximum binding - counts/minutes non-specific binding) x
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100. The results were then plotted against the corresponding standard concentration, and
the insulin concentration of test samples was read directly from the standard curve.

RIA for IGF-I. IGF-I, IGF-II, and IGFBP-3 binding protein levels were assayed
by Kathy Gallego in the laboratory of Dr. E. Martin Spencer at California-Pacific
Medical Center.

Separation of IGFBP-3 from IGF-I. All samples were extracted prior
to RIA analysis with acid-ethanol to remove interference from endogenous binding
proteins by a modification of the method of Daughaday et al. 23

All samples were

chromatographed on the Waters C18 Sep Pak cartridge that was activated by passing in
sequence 3 ml of acetonitrile, followed by 3 ml of distilled water, and then 3 ml of 0.1%
aqueous trifluoroacetic acid (TFA).

0.2 ml of sample was acidified with 1.3 ml of 1%

TFA solution, mixed and applied to the cartridge after 10 minutes at room temperature.
It was possible to leave the sample in 1 % TFA solution for several hours without loss
of activity. Then, the entire sample was aspirated or forced through the Sep Pak slowly,
1 to 5 minutes. Subsequently, the tube containing the sample was washed with two 1 ml
portions of 0.1 % TFA and each applied to the cartridge in succession. After this, a final
1 ml of 0.1 % TFA was used to wash the column.

The washing procedure assured a

quantitative transfer of the sample and removal of the dissociated carrier protein from the
CI8 cartridge. The samples were eluted using 2.2 ml of 0.1 % TFA in acetonitrile. After
extraction, the samples were dried by removing the acetonitrile under vacuum using a
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Savant Speed Vac Concentrator (Savant Instruments, Farmingdale, NY), reconstituted
in 0.5 ml of RIA buffer, and adjusted to pH 7.4 with 2 M Tris.

RIA
Rea sents.

The RIA buffer consisted of 30 mM phosphate containing

0.25% human serum albumin and 0.02% sodium azide at pH 7.4. The primary antibody
was prepared by Reber and Liske 79.

Rabbits were immunized with human IGF-I

purified by Ritschard and Roncari at Hoffman-La Roche (Basel, Switzerland) from
human Cohn fraction IV.

The immunization material contained a single peptide as

determined by physiochemical and N-terminal microsequence analysis and performed at
a level that would detect greater than 10% contamination.

Its cross-reactivity with rat

somatomedin-C was 35% and 3% with rat and human IGF-II. No cross-reactivity was
observed with growth hormone, prolactin, insulin, glucagon, epidermal growth factor,
and bradykinin. IGF-I antiserum was diluted 5,000 fold in the RIA buffer. IGF-I was
iodinated using solid-phase lactoperoxidase beads according to the protocol supplied by
Biorad (Richmond, CA). The labeled polypeptide was separated from the free 125I by
Sephadex G-50 chromatography in 50 mM Tris-HCl pH 7.4 containing 0.25% human
serum albumin. The specific activity averaged 200 ^Ci//xg. 125I-IGF-I was diluted in the
RIA buffer and contained 10% Bacitracin solution.

The secondary antibody was goat

anti-rabbit gamma globulins (Antibodies, Inc.) titrated to 1:20 with the RIA buffer. The
precipitating reagent was RIA buffer less BSA plus 6.4% PEG 8000 (Sigma).
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Procedure. The RIA was set up as described above, and each sample and
standard were measured in duplicate. The assay volume was 0.4 ml and contained the
rabbit anti-IGF-I in a final dilution of 1:9,000 and 15,000 cpm of 125I-IGF-I.

The

incubation was carried out at 4°C for 18 hours. The free 125I-IGF-I was separated from
bound by addition of rabbit gamma globulin (final concentration 1:900) and goat anti¬
rabbit gamma globulin (final concentration 1:120) plus PEG precipitation (final
concentration 4%).

After incubation for 15 minutes at 4°C, the pellet was precipitated

by centrifugation at 3,000 x g for 30 minutes at 4°C. The inter-assay variation was 5.9%
and intra-assay variation was 7 %. Calculations of concentrations were done as described
above.

RIA for IGF-II

Separation of IGFBP-3 from IGF-II.

Samples were processed using a

modification of the acid-ethanol procedures described above. 0.05 ml extraction buffer
(8.0 M formic acid, [Fisher A-119]; 0.5% Tween-20, SurfactAmps-20, 10% solution,
[Pierce 28320] and acetone [reagent grade]) was added to each 0.1 ml sample.

The

solution was mixed and centrifuged at 4°C for 20 minutes at 3,000 x g. The supernatant
was then diluted with RIA assay buffer (50 mM sodium phosphate monobasic [Sigma S9638], 0.1% sodium chloride [Fisher S-671], 0.1% EDTA, disodium salt [Sigma E4884], 0.1% sodium azide [Sigma S-2002], 0.02% protamine sulfate [Sigma P-4020],
and 0.05% Tween-20 [SurfactAmps-20, 10% solution, Pierce 28320] at pH 7.5) yielding
a final net dilution of 1:500.
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RIA
Reagents. Human IGF-II (hIGF-II) monoclonal antibody (Clone S1-F2, Amano
Pharmaceutical Co., Ltd.) was reconstituted with deionized water to yield a dilution of
1:1,000. 125I-hIGF-II (obtained from Mr. E. W. Schirmer, MC797) was prepared with
assay buffer to give a final concentration of 500 pg/ml.

Normal mouse serum (NMS)

(Calbiochem 566442) was prepared by mixing it with assay buffer less protamine sulfate
plus 0.2% gelatin (bovine Skin Type IV, Sigma Q-6269). The secondary antibody, goat
anti-mouse gamma globulin (Calbiochem 401210) and PEG (Sigma E-4884) was mixed
with assay buffer to make the precipitating reagent. Lilly Corporate Reference standards
hlGF-II ([Lot RS0059] 0.05-50.00 ng/ml) were prepared by mixing with 10 mM HC1
to a concentration of 1 mg/ml, verified by measuring absorbance at 276 nm.

Procedure.

Standards and test samples were assayed in duplicate. The assay

volume was 0.3 ml and contained the mouse anti-IGF-II in a final dilution of 1:3,000 and
15,000 cpm of 125I-IGF-II. The incubation was carried out at room temperature for 24
hours.

The free 125I-IGF-II was separated from bound by addition of normal mouse

serum and goat anti-mouse gamma globulin plus PEG precipitation.

After 1 hour at

room temperature, the pellet was precipitated by centrifugation at 3,000 x g for 15
minutes at 4°C.

Cross-reactivity with IGF-I was less than 1%.

variations were 8.3 and 4.5%, respectively.

Inter- and intra-assay
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RIA for IGFBP-3
Reagents. The RIA buffer used was 50 mM phosphate at pH 7.5 containing 0.1
% sodium chloride, 0.1% EDTA, 0.1% sodium azide, 0.02% protamine sulfate, and
0.05% Tween-20. The primary antibody was a polyclonal antibody prepared in rabbit
host by the Laboratory of Growth and Development at California-Pacific Medical Center,
San Francisco, CA. It was diluted in the RIA buffer to a titer of 1:2,667. 12SI-IGFBP-3
was diluted with RIA buffer to give 5 ng/1 mCi 123Iodine. The secondary antibody was
goat anti-rabbit gamma globulins (Antibodies, Inc.) titrated to 1:20 with the RIA buffer.
The precipitating reagent used was 6.4% PEG 8000 (Sigma) in 30 mM sodium phosphate
and 0.02% sodium azide at pH 7.4. Standards were prepared by serial dilution ranging
from 3.4-200 ng/ml.

Procedure. All samples and standards were measured in duplicate.

The assay

volume was 0.3 ml and contained the rabbit anti-IGFBP-3 in a final dilution of 1:8,000
and 15,000 cpm of 125I-IGFBP-3. The incubation was carried out at 4°C for 48 hours.
The free 123I-IGFBP-3 was separated from bound by addition of rabbit gamma globulin
(final concentration 1:900) and goat anti-rabbit gamma globulin (final concentration
1:120) plus PEG precipitation (final concentration 4%).

After 15 minutes at 4°C, the

pellet was precipitated by centrifugation at 3,000 x g for 25 minutes at 4°C. The inter¬
assay variation was 7%.
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Statistical Considerations. (Performed by author). Unpaired student’s two-tailed t-test
was used to test the significance of the difference between means.

When comparing

three groups 1-way analysis of variance (ANOVA) was used, and if there was a
significance, Newman Keul’s test was done to determine significance between individual
means.

Pearson’s method was used to determine correlation.

analysis was also used to determine the best fit curve.

Multiple regression

All results are reported as the

mean (M) + the standard error of the mean (SEM). P value of < 0.05 was considered
significant.
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RESULTS

The Relationship of IGF-I, IGF-II, and IGFBP-3 to Gestational Age
In Table 1, fetal serum IGF-I, IGF-II, and IGFBP-3 levels remained stable
between 21-36 weeks gestation in all fetuses.

At term, large neonates showed a

significant increase in IGF-I levels (53 ± 8 ng/ml and 58 ± 7 ng/ml vs. 86 ± 6 ng/ml,
p<0.05). AG A neonatal IGF-I levels were significantly higher only when compared to
the 21-27 weeks gestation group and not the 28-36 weeks gestation group. Although not
statistically significant, fetal IGF-I levels in the LGA group showed a similar trend.
Fetal IGF-I levels in the small group did not show a significant change from levels
measured during 21-36 weeks gestation.
Using ANOVA, comparison of IGF-II levels between late second trimester (21-27
weeks), early third trimester (28-36 weeks), and each of the term groups was not
statistically significant. However, comparison between two means revealed that IGF-II
levels in the term small group was significantly lower than levels measured during
28-36 weeks gestation (128 ± 30 ng/ml vs. 229 ± 27 ng/ml, p<0.05). The student’s
t-test also showed that in the term large group, IGF-II levels were significantly elevated
compared to levels in the 21-27 weeks gestation group (219 ± 11 ng/ml vs. 177 ± 15
ng/ml, p<0.05).

IGF-II levels in the AGA and LGA groups were similar to levels

measured during 21-36 weeks gestation.
Both LGA and large neonates also had increased IGFBP-3 levels at term (0.80 ±
0.08 /xg/ml and 0.80 ± 0.05 jug/ml vs. 1.10 ± 0.07 Mg/ml, p< 0.05; 0.80 ± 0.08 /^g/ml
and 0.80 ± 0.05 /xg/ml vs. 1.10 ± 0.04 /u,g/ml, p<0.05, respectively). IGFBP-3 levels
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in the AGA and small groups were not statistically different from levels during 21-36
weeks gestation.

In Figures 1 and 2, gestational age positively correlated with IGF-I and IGFBP-3
levels (r= +0.297, p<0.05 and r= +0.386, p<0.01, respectively).

IGF-II levels did

not correlate with gestational age.

Figure 3 shows that during mid and late gestation, fetal serum IGF-I and IGF-II
levels directly correlated with fetal serum IGFBP-3 levels (r= +0.692, p< 0.001 and
r=+0.458, p<0.002, respectively).

The Relationship of Insulin, IGF-I, IGF-II, and IGFBP-3 to Neonatal Weight
There is a direct and positive correlation between neonatal serum IGF-I and
neonatal serum IGFBP-3 levels and birth weight (r= +0.564, p<0.02 and r= +0.503,
p<0.05, respectively) in the AGA group (Figures 4 and 5).

Correlation analysis did

not demonstrate a similar relationship between neonatal IGF-II and birth weight in this
group. Within the LG A, small, and large groups, there was also no correlation between
birth weight and IGFs or binding protein levels.

There was no relationship between

serum insulin levels and birth weight in any group.
When the neonates were classified as AGA and LGA, there was no significant
difference in neonatal serum insulin, IGF-I, IGF-II or IGFBP-3 levels between the two
groups (Table 2). However, when divided into small and large neonates, neonatal serum
IGF-I (40 +11 ng/ml vs. 86 + 6 ng/ml, p<0.01), IGF-II (128 + 30 ng/ml vs. 219
+ 11 ng/ml, p<0.01), and IGFBP-3 levels (0.7 + 0.25 /xg/ml vs. 1.1 + 0.04 jug/ml.
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p < 0.01) were significantly higher in the large neonates.

The insulin levels were

comparable between these two groups (Figures 6 and 7).

Maternal Serum Insulin, IGF-I, IGF-II, and IGFBP-3 Levels
Table 3 shows maternal serum insulin, IGF-I, IGF-II, and IGFBP-3 levels during
early (trimester 1) and late pregnancy (term).

At term, maternal serum IGF-I and

IGFBP-3 levels were significantly higher than maternal levels during early pregnancy.
This finding was not observed with insulin or IGF-II levels in any of the 4 term groups.
In Figure 8, in the AG A group, maternal serum IGF-I levels were found to increase
along with maternal serum IGFBP-3 levels.

Maternal serum IGF-II levels did not

correlate with IGFBP-3 levels in this group. In Figure 9, similarly in the large group,
maternal IGF-I levels directly correlated with maternal IGFBP-3 levels.
was no relationship between maternal IGF-II and IGFBP-3 levels.

Again, there

There also was no

correlation between maternal serum IGFs and IGFBP-3 levels within the LGA and small
groups.

Table 4 shows that there was no significant difference in maternal peptides levels
between AG A and LGA neonates.

Maternal peptides levels between small and large

groups also did not differ significantly (Table 5).
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The Relationship Between Maternal and Neonatal Insulin, IGF-I, IGF-II and IGFBP-3
Levels
Figures 10 and 11 compare maternal and neonatal peptides levels within the LG A
and AGA groups.

Within each group, maternal serum levels of IGF-I, IGF-II, and

IGFBP-3 were significantly higher than the neonatal levels.

There was a significant

difference between maternal and neonatal levels of insulin in the AGA group but not the
LG A group.
Figures 12 and 13 also compare peptides levels in maternal and neonatal
compartments but within small and large neonates.

Again, maternal serum levels of

IGF-I, IGF-II, and IGFBP-3 were significantly higher than neonatal levels.

Similarly,

in the large group, but not the small group, maternal serum levels of insulin were
significantly higher than neonatal levels.

Amniotic Fluid IGF-I, IGF-II, and IGFBP-3 Levels
Table 6 shows the comparison of maternal, neonatal, and amniotic fluid peptides
levels of AGA term neonates. Neonatal serum IGF-I, IGF-II, and IGFBP-3 levels were
similar to amniotic fluid levels (105 ± 6 ng/ml vs. 124 + 41 ng/ml; 215 ± 27 ng/ml
vs. 299 ±81 ng/ml; 1.10 ± 0.08 /rg/ml vs. 1.80 ± 0.30 /xg/ml, respectively), and both
were lower than maternal levels (343 ± 55 ng/ml, p<0.01; 510 ± 45 ng/ml, p<0.01;
3.90 ± 0.20 /rg/ml, p<0.01, respectively).
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Insulin and Type 1 IGF Receptors in Placental Membranes
Insulin and type 1 IGF receptors were semi-quantitatively assayed using
immunohistochemical techniques. Four different intensities of staining were observed,
and results were reported as trace positive, slight positive, moderately positive, and
strongly positive. Type 2 IGF receptors were not assayed because antibodies were not
commercially available.

Figures 14-17 show the negative controls of insulin receptor staining.
stained tissue were red blood cells.

The

Figures 18-21 are representative of the insulin

receptors stained in the first trimester placenta and in the amnion, chorion/decidua, and
placental tissue of term AG A placenta.

All (7/7) of the first trimester placenta, term

amnion tissue, and term chorion/decidua tissue stained strongly positive. Although also
present in 100% of term placental tissue, the receptors stained only moderately positive.

Figures 22-25 show negative control for type 1 IGF receptor staining.

The

stained tissue were red blood cells. Figures 26-29 are representative of the type 1 IGF
receptors identified in first trimester placenta and term placental tissues. All (7/7) of the
first trimester placenta stained strongly positive for type 1 IGF receptors. While 100%
of term amnion did contain type 1 IGF receptors, they were only moderately stained.
Type 1 IGF receptors were detected in only 56% (4/7) of the chorion/decidua tissue, and
all were trace positive.

In placental membranes, type 1 IGF receptors were identified

in all samples as slight positive staining.
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DISCUSSION

Our investigation produced the following findings:

(1) fetal IGF-I, IGF-II, and

IGFBP-3 remained stable between 21-36 weeks; (2) fetal serum IGF-I and IGFBP-3
correlated directly with fetal age and birth weight; (3) large neonates had higher IGF-I,
IGF-II, and IGFBP-3 levels than small neonates; (4) maternal IGF-I levels correlated
directly with maternal IGFBP-3 levels, and both were significantly higher at delivery than
during first trimester; (5) at term, maternal serum levels of IGF-I, IGF-II, and IGFBP-3
were significantly higher than both neonatal and amniotic levels; (6) insulin was also
present in both maternal and fetal sera but was not associated with birth weight in normal
neonates; and (7) insulin and type 1 IGF receptors were detectable in placental
membranes

as

early

as

7

weeks

gestation and

were

present

in the

amnion,

chorion/decidua, and placental tissues at term.
IGF-I and IGF-II elicit classical insulin effects on all target tissues of insulin and
have been shown to be potent growth promoting stimuli for many different cultured cells
in vitro. 3-11,32’34- 35> 80- 85-104 Moreover, many clinical and animal studies point to the
relationship between growth and IGF-I levels. The question of whether or not IGFs also
have growth promoting effects of fetal growth in utero has not been definitively
determined.
IGF-I and IGF-II levels have previously been measured in maternal serum and in
cord blood in cross-sectional studies which have yielded conflicting results. 10-35-39-40-55’
, io2,io5

studied changes in insulin, IGF-I, IGF-II, IGFBP-3 levels as well as insulin

82

and

type

1

IGF receptors

throughout

pregnancy,

in both maternal

and

fetal
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compartments.

We used a highly specific RIA in an attempt to resolve this conflict

surrounding the growth promoting effect of IGF in the fetus.
In the present study we demonstrated that fetal IGF-I, IGF-II, and IGFBP-3
remained stable between 21-36 weeks.

Our longitudinal approach established that in

large neonates, significant increases of IGF-I occurred in fetal serum but not until 36
weeks gestation.

Although we also expected LGA neonates to have a significant

elevation in IGF-I levels, we only observed a rise that was not statistically significant.
This finding perhaps was due to the small number of subjects in the LGA group.
Conversely, while we did not expect a significant difference in IGF-I levels in the AG A
group, we found that they were significantly higher when compared to levels measured
in the 21-27 weeks gestation group.

Since the levels were not significantly different

from levels from the 28-36 weeks gestation group, this observation most likely was due
to the fact some of the neonates in the large group also qualified to be included in the
AGA group.
We were able to show that IGF-I levels had a positive relationship with gestational
age during late second trimester through term when we used correlation analysis even
though they did not change significantly between 21-36 weeks gestation by unit analysis.
Perhaps the increment of elevation over time is small such that correlation analysis will
be able to show a significant trend since it examines a continual change and unit analysis
will not be able detect such a change.

In addition to previous studies that have

demonstrated this finding, 10,39,41 Lassarre et al. 55 found a positive correlation between
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serum levels of both IGF-I and IGF-II and hPL after 33 weeks gestation, suggesting that
hPL may have a regulatory role in IGFs synthesis by the human fetal liver.
The comparison of IGF-II levels during late second trimester, early third
trimester, and at term (all four groups) by ANOVA was not statistically significantly.
However, since the raw data suggested that there was clinical significance, we compared
IGF-II levels in the term small neonates and term large neonates with levels during 21-27
weeks gestation and 28-36 weeks gestation and found that IGF-II levels in small neonates
were significantly lower than the 28-36 weeks gestation group, and IGF-II levels in the
large neonates were significantly higher than the 21-27 weeks group.

We expected to

but failed to find a significant difference when comparing IGF-II levels in the small
group to the late second trimester group, which may suggests that IGF-II levels are
reduced at term but only in small neonates and that the relative reduction is small.
Nevertheless, because we were not able to establish a best fit curve between gestational
age or birth weight and IGF-II levels, the lack of significance when compared to late
second trimester is may be related to the small number of subjects in the small group.
Our only explanation for why IGF-II levels in the large neonates were significantly
higher than levels in the 21-27 weeks gestation group but were not significant when
comparing between late second trimester and early third trimester is that the variance in
the early trimester group was unusually large. While several previous studies also did
not identify a relationship between gestational age and fetal IGF-II, 5’41,110 Bennett et

al. 10 did demonstrate that fetal age correlated with IGF-II levels in normal term and
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preterm infants. These data indicate that the relationship between fetal IGF-II levels and
the duration of gestation needs to be further clarified in a larger study.
Our study, however, did show that IGF-I, IGF-II, and IGFBP-3 all exhibited
similar trends during mid and late gestation.

Therefore, it seems conceivable that,

although both peptides and the binding protein may interplay to regulate fetal growth,
IGF-II is not the dominant hormone influencing growth.

It can also be postulated that

by measuring the circulating levels of IGF-I and IGF-II we evaluated only the endocrine
action of these peptides on intrauterine growth and not their possible paracrine action.
Conflicting information have been reported regarding the relationship between
IGF levels and neonatal birth weight, which is partly due to the different criteria used
to divide study subjects and partly due to the use of many different assay techniques. We
chose to divide the neonates using two different criteria in order to properly analyze the
data in comparison to previously studies.
When we classified our neonatal subjects as small or large, we found that large
neonates had significantly higher levels of IGF-I, IGF-II, and IGFBP-3 than small
neonates. Our findings agree with a recent study conducted by Lassarre et al. 55 Using
the same classification, they studied IGF-I, IGF-II and their binding protein in the fetal
circulation in both normal and intrauterine growth retarded fetuses and found a significant
association between IGF-I levels and fetal weight. While many reports have also shown
a positive correlation between IGF-I levels at term and birth weight, 5'7i 10,24,41,50,102
Wang et al. 105 measured IGF-I and IGFBP-3 in the maternal circulation as well as in
cord blood of SGA and AGA neonates and found an inverse correlation between IGF-I
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levels in the umbilical artery and vein and birth weight.

The authors concluded that

while it is very likely that fetal growth is influenced by the interaction between IGF-I,
IGFBP-3, and their receptors at the local tissue levels, the circulating concentration of
IGF-I and IGFBP-3 may only indirectly reflect their activity.
While there was a positive correlation between fetal IGF-I levels and birth weight,
no such relationship existed with IGF-II in our study.

Bennett et al., 10 however,

reported that IGF-II correlated with birth weight, but only in term and not preterm
infants.

Since they also used specific RIAs to measure IGFs levels, their method of

dividing the study subjects (excluding all neonates whose weights were greater or less
than two standard deviations from the mean) is the only factor that can account for this
contrast, although it is unlikely. Our finding that insulin levels were comparable in all
neonates regardless of birth weight further strengthens our hypothesis that IGF-I has an
important role in the control of intrauterine growth.
In this investigation we measured only IGFBP-3 levels.

Our data showed that

during fetal life, IGFBP-3 production is adapted to the increase the bioavailability to
IGF-I synthesis.

We have also determined that IGFBP-3 levels correlated with

gestational age and birth weight and were significantly higher in large neonates when
compared to small neonates. Since it has been demonstrated that binding of proteins to
IGFs abolishes their activity,46 it is plausible that in large neonates or fetuses with above
normal acceleration of growth at term, one of the mechanisms to control the growth rate
is to decrease the biologically active IGF concentration via increasing production of
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IGFBP-3. Our finding therefore supports the role of binding proteins in the regulation
of fetal growth.
Maternal serum IGFBP-3 levels also rose during the third trimester, concomitant
with increasing maternal IGF-I levels, indicating that there is an association between
1GF-I and IGFBP-3. Despite similar observations with fetal serum IGF-I and IGFBP-3
levels, it is very unlikely that there is placental transfer of the peptides as both are
greater than 1000 daltons. 66,99

Moreover, in all neonates, maternal levels of IGF-I,

IGF-II, and IGFBP-3 were significantly higher than neonatal levels.

This implies that

IGF-I production in the maternal and fetal compartments are independent of each other.
These results are in agreement with previous studies. 7> 8i 38,84
In the maternal compartment, our study showed that IGF-I and IGFBP-3 were
significantly higher at delivery than during first trimester, but there was no association
between maternal IGF-I and IGF-II levels and neonatal birth weight. Our results agree
with previous studies 37,108,110 that maternal IGF-I concentration correlated significantly
with the duration of gestation but not with neonatal birth weight. These data, along with
the unlikelihood that there is placental transfer of IGFs, suggest that maternal IGF-I
does not have a direct role in fetal growth.

Wilson et al. 110 found that maternal

IGF-II during the third trimester was significantly higher than the first trimester.

Our

results conflict and we cannot offer an explanation for this discrepancy as IGFs levels
were measured using the same techniques in both studies.

However, since both

Furlanetto et al. 37 and Wilson et al. 110 demonstrated that during the post partum period,

*
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there was a striking decline in maternal IGF-I and IGF-II, it is possible that maternal
IGFs primarily regulate placental growth which indirectly affects fetal growth.
We demonstrated that fetal and amniotic fluid levels of IGFs and IGFBP-3 were
similar, suggesting that exchange can exist between the two compartments. Merimee et

al. 63 studied IGF-I, IGF-II, IGFBP-1, and IGFBP-3 in amniotic fluid and found that
while IGF-I concentration was constant throughout
precipitously during late gestation.

gestation,

IGF-II

decreased

The total binding protein levels decreased

significantly during mid gestation and remained constant during the last period of
gestation. The authors concluded that the distinct pattern of IGF-II and IGFBPs variation
suggests a dynamic control of IGF in the amniotic fluid during normal pregnancy. Since
Fant et al. 33 reported that binding proteins were produced by preterm but not term
placenta and Povoa et al. 78 demonstrated that IGFBP isolated from a human hepatoma
cell line was identical to the human amniotic fluid IGFBP, it is possible that during early
gestation, the placenta, in addition to fetal liver, serves as a source of IGFs and binding
protein.

Amniotic fluid then functions as a reservoir for IGF-I, IGF-II, and IGFBP-3

throughout gestation should it become necessary for the fetus to modulate growth in
response to stressors.
Our study showed that maternal serum insulin levels did not differ significantly
between any of the four term groups and neither maternal nor fetal/neonatal insulin levels
correlated with birth weight in normal neonates. These findings suggest that in normal
pregnancy, insulin does not have the primary role in regulating fetal growth. When we
compared maternal and neonatal sera insulin levels, we found that maternal levels were
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significantly higher only in the AGA and large groups.

Again, we attribute these

observations to the fact that the AGA and large groups included some of the same study
subjects.

Although maternal levels are higher than neonatal levels in two of the four

groups, we believe that this is not relevant in the control of fetal growth because it is
well accepted that insulin does not cross the placental barrier and all of our subjects are
non-diabetic.
Insulin and type 1 IGF receptors were detected in all first trimester placental
membranes as early as 7 weeks gestation and in the amnion, chorion/decidua, and
placental tissues of term placentas. Type 1 IGF receptors stained more strongly in first
trimester placentas than in term placentas while insulin receptors stained relatively
equally throughout. These results may reflect a down regulation of the type 1 IGF
receptors in the presence of high IGF-I levels and conversely lack of down regulation of
the insulin receptors in the presence of stable insulin levels.
In conclusion, the data presented in this study demonstrated the bioavailability of
other in utero fetal growth promoters

(IGF-I and IGF-II),

their binding protein

(IGFBP-3), and their receptor (type 1 IGF) during mid and late gestation. We showed
that fetal levels of IGF-I and IGFBP-3 were associated with gestational age and fetal birth
weight and demonstrated that large neonates had significantly higher levels of IGFs and
IGFBP-3 than small neonates at birth in normal pregnancies.

We also established that

maternal and fetal IGF-I, IGF-II, and IGFBP-3 are produced and most likely act
independently of each other.

Whether or not fetal IGF-I in conjunction with fetal

IGFBP-3 and IGF-II can account for the excessive growth seen in diabetes or whether
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it can be used to treat fetal growth reduction remain unknown and will require further
study.
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TABLES AND FIGURES

Gestational Age
(Weeks)

Fetal IGF-I
(ng/ml)

Fetal IGF-II
(ng/ml)

21-27 (n=13)

53 ± 8

177 ± 15

0.80 ± 0.08

28-36 (n=19)

58 ± 7

229 ± 27

0.80 ± 0.05

38-41 / AGA (n=18)

79 ± 8*

208 ± 17

0.96 ± 0.05

38-41 / LGA

77 ± 12
(n=8)

199 ± 8
(n=8)

1.10 ± 0.07*+
(n=9)

38-41 / Small (n=4)

40 ± 11

128 ± 30+

0.70 ± 0.25

38-41 / Large

86 ± 6*+
(n=22)

219 ± 11*
(n=22)

1.10 ± 0.04*+
(n=23)

TABLE 1:

Fetal IGFBP-3
(^tg/ml)

Fetal Serum IGF-I, IGF-II, and IGFBP-3 Levels During Pregnancy
Mean ± SEM; * p<0.05 vs. Gestational Age 21-27 Weeks;
+ p<0.05 vs. Gestational Age 28-36 Weeks; In the LGA and Large
Groups, 1 data sample for IGF-I and IGF-II was not available due to
technical difficulty with the assay and subsequently insufficient serum.

41

GESTATIONAL AGE (weeks)

FIGURE 1: Relationship Between Fetal Serum IGF-I
Levels and Gestational Age
n = 58; r = + 0.297; p < 0.05
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GESTATIONAL AGE (weeks)

FIGURE 2: Relationship Between Fetal Serum IGFBP-3
Levels and Gestational Age
n = 59; r = + 0.386; p < 0.01
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PEPTIDE CONCENTRATION (ng/ml)

FIGURE 3: Relationship Between Fetal Serum IGF-I
and IGF-B Levels and Fetal Serum IGFBP-3
Levels During Mid and Late Gestation

0

IGF-I

n = 58; r = + 0.692; p < 0.001

♦

IGF-II n = 58; r = + 0.458; p < 0.002
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BIRTH WEIGHT (grams)

FIGURE 4: Relationship Between Neonatal Serum IGF-I Levels
and Birth Weight in AGA Group
n = 18; r = + 0.564; p < 0.02

[NEONATAL IGFBP-3] (ug/ml)
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BIRTH WEIGHT (grams)

FIGURE 5: Relationship Between Neonatal Serum IGFBP-3
Levels and Birth Weight in AGA Group
n = 18; r = + 0.503; p < 0.05
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Gestational Age (weeks)
Weight (grams)

!

AGA (n = 18)

LGA (n = 9)

p Value

40 + 0

40 ± 1

—

3315 ± 68

4294 + 120

—

Neonatal Insulin (/tU/ml)

16 ± 1

18 + 5 (n = 8)

NS

Neonatal IGF-I (ng/ml)

79 + 8

77 + 12 (n = 8)

NS

Neonatal IGF-II (ng/ml)

208 ± 17

199 + 8 (n = 8)

NS

0.96 ± 0.05

1.10 + 0.07

NS

Neonatal IGFBP-3 0*g/ml)

TABLE 2:

Neonatal Serum Insulin, IGF-I, IGF-II, and IGFBP-3 Levels in AGA and
LGA Groups
Mean + SEM; NS = not significant
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FIGURE 6: Neonatal Serum Insulin, IGF-I,
and IGF-II Levels in Small and Large Neonates
■ SMALL (n =4)

M LARGE (n=22)
* p < 0.01

CONCENTRATION (ug/ml)
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IGFBP-3

FIGURE 7: Neonatal Serum IGFBP-3 Levels in
Small and Large Neonates

■ SMALL (n=4)

M LARGE (n=23)
* p < 0.001
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Maternal
Insulin

(nV/ml)

Maternal
IGF-I
(ng/ml)

Maternal
IGF-II
(ng/ml)

Maternal
IGFBP-3
(jtg/ml)

Trimester 1 (n = 7)

22 + 4

145 ± 15

535 ± 33

2.50 ± 0.20

Term / AGA (n=18)

31+5

387 ± 35*

602 ± 32

3.60 ± 0.10*

Term / LGA (n = 9)

28 + 7

391 ± 28*

583 ± 59

3.50 ± 0.10*

Term / Small (n=4)

26 + 5

412 ± 86+

622 ± 101

3.30 ± 0.30#

Term / Large (n=23)

30 + 5

384 ± 26*

591 ± 30

3.60 ± 0.10*

TABLE 3:

Maternal Serum Insulin, IGF-I, IGF-II, and IGFBP-3 Levels During Early
(Trimester 1) and Late Pregnancy (Term)
Mean ± SEM; * p< 0.001 vs. Trimester 1; + p<0.02 vs. Trimester 1;
tt p<0.05 vs. Trimester 1
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[MATERNAL IGF-I] (ng/ml)

FIGURE 8: Relationship Between Maternal Serum
IGF-I and IGFBP-3 Levels in AGA Group
n = 18; r = + 0.640; p < 0.01
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[MATERNAL IGF-I] (ng/ml)

FIGURE 9: Relationship Between Maternal Serum
IGF-I and IGFBP-3 Levels in Large Group
n = 23; r = +0.518; p < 0.02
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AGA (n = 18)

LGA (n = 9)

p Value

40 ± 0

40 ± 1

—

3315 ± 68

4294 ± 120

-

31+5

28 + 7

NS

Maternal IGF-I (ng/ml)

387 ± 35

391 ± 28

NS

Maternal IGF-II (ng/ml)

602 ± 32

583 ± 59

NS

3.60 ± 0.10

3.50 ± 0.10

NS

Gestational Age (weeks)
Weight (grams)
Maternal Insulin (/xU/ml)

Maternal IGFBP-3 (jig/ml)

TABLE 4:

Maternal Serum Insulin, IGF-I, IGF-II, and IGFBP-3 Levels in AGA and
LGA Groups
Mean ± SEM; NS = not significant
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SMALL (n = 4)

LARGE (n = 23)

p Value

40 + 0

38 + 2

—

2898 ± 108

3770 ± 104

—

26 + 5

30 + 5

NS

Maternal IGF-I (ng/ml)

412 ± 86

384 ± 26

NS

Maternal IGF-II (ng/ml)

622 ± 101

591 ± 30

NS

3.30 ± 0.30

3.60 ± 0.10

NS

Gestational Age (weeks)
Weight (grams)
Maternal Insulin (/tU/ml)

Maternal IGFBP-3 (fig/ml)

TABLE 5:

Maternal Serum Insulin, IGF-I, IGF-II, and IGFBP-3 Levels in Small and
Large Groups
Mean ± SEM; NS = not significant
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FIGURE 10: Comparison of Maternal and Neonatal IGF-I and IGF-II
Levels within LGA and AGA Neonates

■ LGA - MATERNAL (n = 9)

H LGA - NEONATAL (n = 8)

M

□ AGA - NEONATAL (n = 18)

AGA - MATERNAL (n = 18)

* p < 0.001
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INSULIN

IGFBP-3

FIGURE 11: Comparison of Maternal and Neonatal Insulin and
IGFBP-3 Levels within LGA and AGA Neonates

■ LGA-MATERNAL (n = 9)

M AGA - MATERNAL
* p < 0.001

H LGA - NEONATAL (n = 8)

(n = 18) E2

AGA - NEONATAL (n = 18)

CONCENTRATIONS (ng/ml)
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FIGURE 12: Comparison of Maternal and Neonatal IGF-I and IGF-II Levels
within Small and Large Neonates
■

SMALL-MATERNAL (n = 4)

B

SMALL-NEONATAL (n = 4)

fH LARGE-MATERNAL (n = 23) □ LARGE-NEONATAL (n = 22)
* p < 0.01; +p< 0.005; #p< 0.001

-*•

57

FIGURE 13: Comparison of Maternal and Neonatal Insulin and IGFBP-3 Levels within
Small and Large Neonates

■

SMALL-MATERNAL (n =4)

M

LARGE-MATERNAL (n=23) □

S3

SMALL-NEONATAL (n = 4)
LARGE-NEONATAL (IGFBP-3; n=23 / INSULIN; n=22)

(1 data sample for insulin in the large neonatal group was not available due to technical
difficulty with the assay and subsequently insufficient serum.)

p < 0.01; + p < 0.001
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IGF-I (ng/ml)

IGF-II (ng/ml)

Maternal (n=7)

343 ± 55

510 ± 45

3.90 ± 0.20

Neonatal (n=7)

105 ± 6*

215 ± 27*

1.10 ± 0.08*

Amniotic Fluid (n=7)

124 ± 41*

299 ± 81*

1.80 ± 0.30*

TABLE 6:

IGFBP-3 (ng/m\)

Maternal, Neonatal, and Amniotic Fluid Levels of IGF-I, IGF-II, and
IGFBP-3 in Term AGA Infants
Mean ± SEM; * p<0.01 vs. Maternal Level
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FIGURE 14:

Negative Control of Insulin Receptors Assay. Primary Antibody was Omitted.
Term Chorion/Decidua Tissue. 40x Magnification.

FIGURE 15:

Negative Control of Insulin Receptors Assay. Secondary Antibody was Omitted.
Term Placenta Tissue. 40x Magnification.

FIGURE 16:

Negative Control of Insulin Receptors Assay.
Streptavidin-Horseradish
Peroxidase was omitted. Term Amnion Tissue. 40x Magnification.

FIGURE 17:

Negative Control of Insulin Receptors Assay.
Placenta Tissue. 40x Magnification.

DABA was Omitted.

Term
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FIGURE 18:

First Trimester Placenta. Strongly Positive Stained Insulin Receptors.
Samples. 20x Magnification.

FIGURE 19:

Term Amnion Tissue. Strongly Positive Stained Insulin Receptors. 7/7 Samples.
40x Magnification.

7/7
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FIGURE 20:

Term Chorion/Decidua Tissue. Strongly Positive Stained Insulin Receptors. 7/7
Samples. 40x Magnification.

FIGURE 21:

Term Placental Tissue. Moderately Positive Stained Insulin Receptors.
Samples. 40x Magnification.

7/7
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FIGURE 22:

Negative Control of Type 1 IGF Receptors Assay. Primary Antibody was
Omitted. Term Chorion/Decidua Tissue. 40x Magnification.

FIGURE 23:

Negative Control of Type 1 IGF Receptors Assay. Secondary Antibody was
Omitted. Term Placenta Tissue. 40x Magnification.
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FIGURE 24:

Negative Control of Type 1 IGF Receptors Assay. Streptavidin-Horseradish
Peroxidase was Omitted. Term Placenta Tissue. 40x Magnification.

FIGURE 25:

Negative Control of Type 1 IGF Receptors Assay. DABA was Omitted. Term
Placenta Tissue. 40x Magnification.
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FIGURE 26:

First Trimester Placenta. Strongly Positive Stained Type 1 IGF Receptors. 7/7
Samples. 40x Magnification.

FIGURE 27:

Term Amnion Tissue. Moderately Positive Stained Type 1 IGF Receptors. 7/7
Samples. 40x Magnification.
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FIGURE 28:

Term Chorion/Decidua Tissue. Trace Positive Stained Type I IGF Receptors.
4/7 Samples. 40x Magnification.

FIGURE 29:

Term Placental Tissue. Slightly Positive Stained Type 1 IGF Receptors.
Samples. 40x Magnification.

7/7
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